We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital

By LabMedica International staff writers
Posted on 08 Jul 2024
Print article
Image: The rapid drug test could provide patients with better care (Photo courtesy of Colonial Foundation)
Image: The rapid drug test could provide patients with better care (Photo courtesy of Colonial Foundation)

A team of researchers is developing advanced solutions to rapidly test for drugs and improve the treatment of patients presenting to the hospital.

The researchers from the Colonial Foundation Healthy Ageing Centre (Melbourne, VIC, Australia) are employing mass spectrometry technology to rapidly detect any medications or drugs that might complicate a patient's treatment. This rapid identification is crucial to ensure that patients receive appropriate care and to minimize the effects of any previously administered medications or drugs. Mass spectrometry identifies and quantifies chemicals in a sample using charged particles, or ions, proving to be more precise than traditional immunoassays, which can sometimes yield false positives.

In their recent research, published in the Medical Journal of Australia, the research team demonstrated that traditional testing methods could mistakenly show toxic levels of a heart failure medication due to interference from a common prostate cancer drug. However, when mass spectrometry was used for the same test, it successfully identified and corrected this interference. Consequently, the patient was spared unnecessary treatments, allowing clinicians to address the true medical issue. This advancement has the potential to improve patient outcomes by enabling more accurate treatment decisions. The researchers plan to further expand the testing capabilities of this technology, broadening its application and advancing personalized medicine, which focuses on customizing treatment based on individual patient needs.

“This new-age technology is enabling our teams to provide more specific results, and therefore treatment options, to our clinicians in real-time,” said Cherie Chiang, Associate Professor and researcher at the Colonial Centre. “As a result, we can provide patients with more personalized treatment plans and greater care.”

Related Links:
Colonial Foundation Healthy Ageing Centre

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.